Abbonarsi

États de mal épileptiques non convulsifs de l’adulte : quelles nouveautés ? - 20/02/13

Doi : 10.1016/j.praneu.2013.01.002 
V. Bourg , M. Laffon, F. Martin, P. Thomas
UF EEG, épileptologie et service de neurologie, hôpital Pasteur, 30, voie Romaine, BP 69, 06002 Nice, France 

Auteur correspondant : UF EEG, épileptologie et service de neurologie, hôpital Pasteur, 30, voie Romaine, BP 69, 06002 Nice, France.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 11
Iconografia 7
Video 0
Altro 0

Résumé

Les états de mal non convulsifs (EMNC) de l’adulte sont séparés en deux formes, l’état d’absence (EA) et l’état de mal partiel complexe (EMPC). Le diagnostic nécessite la réalisation d’un électroencéphalogramme (EEG) d’urgence. L’EA est la forme la plus fréquente. Il est caractérisé par une confusion fluctuante, d’intensité variable, souvent associée à des myoclonies palpébrales. L’EEG montre des décharges critiques généralisées qui cèdent sous benzodiazépines (BZ) alors que la conscience se normalise. Les EA peuvent survenir dans le cadre d’une épilepsie généralisée ou être inauguraux, par exemple chez le sujet âgé, sous l’influence de facteurs métaboliques, toxiques ou médicamenteux. Le pronostic est favorable. Les EMPC sont caractérisés par une confusion d’intensité variable, fluctuante, associée sur l’EEG à des décharges critiques focales. Ils nécessitent un traitement énergique en raison du risque de résistance et de la possibilité de séquelles cognitives. Les formes frontales et temporales sont les plus fréquentes. Le pronostic dépend des comorbidités. La plupart des encéphalopathies survenant en milieu de réanimation ne relèvent pas d’un EMNC, malgré certains aspects EEG trompeurs. De même, les encéphalopathies métaboliques ou toxiques et la maladie de Creutzfeldt-Jakob peuvent poser des problèmes de diagnostic électroclinique, au mieux résolus par l’injection IV de BZ et le suivi évolutif.

Il testo completo di questo articolo è disponibile in PDF.

Summary

Status epilepticus (SE) may be classified into convulsive SE, which must be rapidly stopped to prevent death or neurologic sequelae and nonconvulsive status epilepticus (NCSE), which is usually characterized by some degree of clouding of consciousness. This latter condition constitutes a diagnosis challenge, because it often goes unrecognized or is mistaken for behavioral or psychiatric disturbances. Emergency EEG is the key feature for diagnosis. NCSE are classically divided on the basis of the ictal EEG into absence status (AS), with predominantly symmetrical synchronous ictal discharges and complex partial status epilepticus (CPSE), with continuous or rapidly recurring complex partial seizures that may involve temporal and/or extratemporal regions. Typical AS occurs as part of an idiopathic generalized epilepsy (IGE) most often characterized by absences. The EEG correlates with repetitive absence seizures and shows symmetric and bilaterally synchronous spike-waves. The immediate prognosis is excellent. Atypical AS occurs in patients with symptomatic or cryptogenic epilepsies, or in patients with IGE and inappropriate medication. It is characterized by a fluctuating confusional state with more prominent tonic and/or myoclonic and/or lateralized ictal manifestations. Episodes tend to recur and to be resistant to medication. “De novo” absence status of late onset is characterized by toxic or metabolic precipitating factors leading to seizures in middle-aged or elderly subjects with no previous history of seizures. Patients often have a history of psychiatric illness with multiple psychotropic drug intake. AS with focal features occurs in subjects with a pre-existing or newly developing localization-related epilepsy, most often of extratemporal origin. The EEG shows bilateral but often asymmetric ictal discharges. CPSE is “a prolonged epileptic episode in which fluctuating or frequently recurring focal electrographic epileptic discharges, arising in temporal or extratemporal regions, result in a confusional state with variable clinical symptoms” (Shorvon, 1994). Various subtypes and precipitating factors are identified. Frontal and temporal localizations are most frequent in clinical practice. Limbic, non paraneoplastic encephalitis with VGKC autoantibodies has a characteristic clinical, MRI and immunological profile. In the recent years, many studies tend to lump together NCSE, “subtle” SE, AS, CPSE, myoclonic SE in coma, and EEG patterns suggestive of SE in comatose patients. In this group, the overall prognosis is poor, with a low response to antiepileptic drugs, but it may be particularly difficult to separate comorbidity to consequent morbidity. Post-hypoxic-ischemic encephalopathy, a life threatening condition that can express itself in the form of coma, EEG changes and myoclonus illustrates such methodological problems. NCSE should obviously be rapidly treated because of the attendant morbidity including physical injury, and because it may evolve on to generalized convulsions. Another argument is that long-term permanent neurologic damage from CPSE has been now documented, especially in the context of limbic encephalitis. IV benzodiazepines (BZ) must be performed first, with a rapid and complete recovery together with a normalization of EEG features. If BZ injection fails, IV fosphenytoin may be the drug of choice, especially in the context of symptomatic CPSE.

Il testo completo di questo articolo è disponibile in PDF.

Mots clés : États de mal épileptique, État absence, État de mal partiel complexe, EEG

Keywords : Status epilepticus, Absence status, Complex partial status epilepticus, EEG


Mappa


© 2013  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 4 - N° 1

P. 11-21 - Febbraio 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Génétique de la maladie de Parkinson
  • E. Mutez, M.-C. Chartier-Harlin, A. Destée
| Articolo seguente Articolo seguente
  • Comment gérer un traitement par Duodopa® dans la maladie de Parkinson évoluée ?
  • C. Moreau, A. Annic, D. Devos, L. Defebvre

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.